The role of targeted therapy in the treatment of advanced hepatocellular carcinoma


Cite item

Full Text

Abstract

Hepatocellular carcinoma (HCC) is the most common cancer in the world. The success of HCC therapy directly depends on diagnosis of early stage of the disease and proper treatment in a timely manner. According to the current recommendations, the systemic standard chemotherapy is not the best option for treating patients with advanced HCC. Nexavar (sorafenib) is currently the only approved targeted drug for the HCC treatment. Sorafenib is the first targeted drug with proven ability to improve overall survival in patients with HCC, compared with placebo. Researchers have already gained extensive experience in treatment HCC using sorafenib within the context of international clinical trials (SHARP, Asia-Pacific, GIDEON), and in actual clinical practice in Russia.

About the authors

E B Shakhnovich

A.V.Vishnevsky Institute of Surgery of the Ministry of Health of the Russian Federation

Email: shakhnovich@yandex.ru
врач-онколог, ФГБУ Институт хирургии им. А.В.Вишневского 117997, Russian Federation, Moscow, ul. Bol'shaia Serpukhovskaia, d. 27

O B Kerbikov

Federal Research Center for Specialized Types of Medical Assistance and Medical Technologies of FMBA of Russia

канд. мед. наук, ст. науч. сотр. ФГБУ ФНКЦ специализированных видов медицинской помощи и медицинских технологий 115682, Russian Federation, Moscow, Orekhovyi bul'var, d. 28

E A Kulaga

M.V.Lomonosov Moscow State University

аспир. фак-та фундаментальной медицины ФГБОУ ВПО МГУ им. М.В.Ломоносова 119192, Russian Federation, Moscow, Lomonosovskii pr., d. 31, korp. 5

References

  1. Sangiovanni A, Prati G.M, Fasani P et al. The natural history of compensated cirrhosis due to hepatitis C virus a 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-10.
  2. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
  3. Bruix J, Sherman M. Management of Hepatocellular Carcinoma: An Update. Hepatology 2011; 53 (3).
  4. Verslype C, Rosmorduc O, Rougier P. ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow - up. Ann Oncol 2012; 23 (Suppl. 7): vii41-8.
  5. http://nccn.org
  6. Практические рекомендации по лекарственному лечению больных первичным раком печени Российского общества клинической онкологии (RUSSCO). Версия 2014; с. 243-52.
  7. Wilhelm S, Carter C, Lynch M et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Dis 2006; 5 (10): 835-44.
  8. Abou-Alfa G.K, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24 (26): 4293-300.
  9. Abou-Alfa G.K, Johanson P, Knox J et al. Preliminary results from Phase II, randomized, double - blind study of sorafenib plus doxorubicin vs. placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. ECCO 14 - European Cancer Conference. Barselona, Spain, 23-27 Sept. 2007.
  10. Cheng A.L, Kang Y.K, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double - blind, placebo - controlled trial. Lancet Oncol 2009; 10 (1): 25-34.
  11. Llovet J.M et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (4): 378-90.
  12. Marrero J et al. Final analysis of GIDEON (Global Investigation of the rapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib) in >3000 sorafenib - treated patients: clinical findings in patients with liver dysfunction. Poster presented at the Annual Meeting of the American Society of Clinical Oncology. May 31 - June 4 2013. Chicago, Illinois USA.
  13. Faivre S, Raymond E, Boucher E et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open - label, multicentre, phase II study. Lancet Oncol 2009; 10 (8): 794-800.
  14. Johnson P.J, Qin S, Park J.W et al. Brivanib vs. sorafenib as first - line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013; 31 (28): 3517-24.
  15. Boige V, Malka D, Bourredjem A et al. Efficacy, safety, and biomarkers of single - agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist 2012; 17 (8): 1063-72.
  16. Zhu A.X, Kudo M, Assenat E et al. EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib. Abstr. J Clin Oncol 2014; 32 (Suppl. 3): 172.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies